New possibilities for treatment of chlamydial infection with enzyme
therapy
I. Mikazans
Clinic of Dermatovenerology of Riga, Latvia
6th Congress of the European Academy of Dermatology and Venerology, September 11 - 15, 1997, Dublin, Ireland - published in JEAVEQ 9 (Suppl,1), 1997, pp S 227, abstract P320.
340 KA
The aim of study was to investigate a new possibility to use systemic enzyme therapy in order to increase the efficiency of pharmacotherapy of Reiter's disease caused by Chlamydia trachomatis.
Material and Method
40 Reiter's disease caused by Chlamydia patient including
28 males and 12 female, 16-51 years old. The patients were divided and
randomized into a study group and a control group.
20 patients of control group received oral standard therapy for two
weeks: doxycyclin 100 mg twice a day and nystatin 500 000 i.u. four
times a day.
20 patients of the study group received standard therapy mentioned above
for 2 weeks plus Wobenzym 5 tablets three times a day for 1 month.
The data obtained showed that for the patients of control group as a
result of standard therapy clinical symptoms after 2 weeks disappeared
in approximately 40%. Symptoms are decrease in 30% patients, and no
changes in 10%. In the study group (additionally to standard therapy
Wobenzym was given for 1 month) clinical symptoms disappeared to nearly
70% of patients, decreased in 24%, and no changes in 6% of patients.
In 1 month the etiological cure (PCR negative) were in 30% patients
that had used standard therapy for 2 weeks. Among the patients who were
treated with Wobenzym additionally for 1 month cure was 75%.
No serious side effects were observed.
Lék pro vnitřní užití. Čtěte pečlivě příbalovou
informaci.
Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750
003